# US 2022/0017851 A1 · Automated biomanufacturing systems, facilities, and processes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017851 A1
- Document ID: US20220017851A1
- Status: Published application
- Kind: A1
- Application number: 17/396,728
- Filed: 2021-08-08
- Published: 2022-01-20
- Earliest claimed: 2019-02-15
- Assignees: Just-Evotec Biologics, Inc.; Merck Sharp & Dohme Corp.
- Applicants: Just-Evotec Biologics, Inc.; Merck Sharp & Dohme Corp.
- Inventors: Michael Wayne Vandiver; Eva Fan Gefroh; Rebecca Eileen McCoy; Robert James Piper, JR.; Mark A. Brower; Nuno J. Dos Santos Pinto; William N. Napoli; Rachel Y. Straughn; Lisa A. Connell-Crowley; Megan J. McClure
- Web page: https://patentgrep.com/patent/US20220017851A1

## CPC

- C12M 41/48: {Automatic or computerized control (automatic analysis G01N35/00)}
- C07K 1/36: by a combination of two or more processes of different types
- C12M 23/28: {disposable or single use}
- C12M 29/04: {Filters; Permeable or porous membranes or plates, e.g. dialysis}
- C12M 29/10: {Perfusion}
- C12M 29/26: {Conditioning fluids entering or exiting the reaction vessel}
- C12M 37/00: {Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination (C12M23/38 takes precedence; filtration in general and filters per se B01D24/00-B01D41/00; autoclaves B01J3/04; treatment of microorganisms with electrical or wave energy C12N13/00)}
- C12M 47/10: {Separation or concentration of fermentation products (bioreactors combined with means for distillation or extraction of liquid fuel C12M43/02)}
- C12M 47/12: {Purification (C12M47/04 takes precedence)}
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Disclosed are a process and an automated facility for manufacturing a purified protein of interest. The protein of interest can be a recombinant or naturally occurring protein and/or a therapeutic or other medically useful protein. For example, the disclosed process and automated facility are useful for manufacturing a purified protein drug substance.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim at position 2

43: An automated facility for manufacturing a purified protein drug substance, the facility comprising:
(a) one or more single-use perfusion bioreactors capable of containing a liquid culture medium under conditions that allow cultured mammalian cells to secrete a protein of interest into the medium for a production cultivation period of at least 10 days; wherein the single-use perfusion bioreactor(s) are adapted to receive fresh sterile liquid culture medium fluidly into each of the perfusion bioreactor(s) in direct relation to volumes of conditioned culture medium that are continuously or periodically removed from each of the perfusion bioreactor(s) as volumes of permeate or cell bleed during the production cultivation period;
(b) a first single-use surge vessel (SUSV1) into which said removed volumes of permeate are automatically and fluidly fed from the one or more single-use perfusion bioreactor(s);
(c) a first chromatography system, adapted to automatically and fluidly receive permeate from the SUSV1, whereby the protein is captured in a protein isolate fraction;
(d) a low pH or detergent viral inactivation system and, if needed, a neutralization system, adapted to automatically and fluidly receive the protein isolate fraction from the first chromatography system, whereby a virally inactivated product pool comprising the protein is obtained;
(e) a holding vessel or a single-use surge vessel, adapted for receiving the virally inactivated product pool;
(f) a second chromatography system adapted to fluidly receive from the holding vessel or single-use surge vessel the virally inactivated product pool, whereby a purified product pool comprising the protein is obtained;
(g) an optional third chromatography system and/or a viral filtration system adapted to fluidly receive the purified product pool comprising the protein from the second chromatography system, whereby a virus-free filtrate comprising the protein is obtained; and
(h) an ultrafiltration/diafiltration system adapted to fluidly receive the virus-free filtrate from the second chromatography system or from the third chromatography system and/or the viral filtration system, whereby the purified protein drug substance is obtained; and
wherein the automated facility is controlled by a process automation system (PAS).

### Claim at position 3 (depends on 43)

44: The automated facility of claim 43, wherein a plurality of reservoirs, each adapted for containing a concentrated medium component solution or aqueous diluent, are fluidly connected to the perfusion bioreactor(s) directly, or indirectly via an optional mixing vessel adapted for receiving from the plurality of reservoirs the concentrated culture medium component solutions and aqueous diluent at predetermined ratios and contemporaneously mixing them, the optional mixing vessel being fluidly connected directly to the perfusion bioreactor(s).

### Claim at position 4 (depends on 43)

45: The automated facility of claim 43, wherein the protein of interest is a recombinant protein.

### Claim at position 5 (depends on 43)

46: The automated facility of claim 43, wherein the protein of interest is a therapeutic protein.

### Claim at position 6 (depends on 43)

47: The automated facility of any of claim 43, wherein the facility is configured for operation in a continuous format.

### Claim at position 7

48-51. (canceled)

### Claim at position 8 (depends on 43)

52: The automated facility of claim 43, comprising in (d): a low pH viral inactivation system and a neutralization system, adapted to automatically and fluidly receive the protein isolate fraction from the first chromatography system, whereby a virally inactivated product pool comprising the protein is obtained.

### Claim at position 9 (depends on 43)

53: The automated facility of claim 43, comprising in (g): a viral filtration system, adapted to fluidly receive the purified product pool comprising the protein from the second chromatography system, whereby a virus-free filtrate comprising the protein is obtained.

### Claim at position 10 (depends on 43)

54: The automated facility of claim 43, comprising in (g): a third chromatography system and a viral filtration system, adapted to fluidly receive the purified product pool comprising the protein from the second chromatography system, whereby a virus-free filtrate comprising the protein is obtained.
